Leerink
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a closely watched late-stage trial, according to results released Sunday. When combined with chemotherapy, the drug kept people with squamous non-small-cell lung cancer alive for a median of four months longer than the standard combination of immunotherapy and chemotherapy, a result that was statistically significant, according to an abstract released Sunday ahead of a presentation at the...
We're picking up more shares of an out-of-favor stock with a bright future
We are buying 50 shares of Johnson & Johnson at roughly $221.43. Following the trade, Jim Cramer's Charitable Trust will own 340 shares of JNJ, increasing its weighting to 1.9% from 1.62%. We're picking up shares of J & J here and lowering our average cost basis as healthcare and drug stocks move lower on Monday.